🐦 推特Wall St EngineCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-31 04:07:42时区推断·⟳ 抓取 07-31 04:07:45·⚡ 决策 08-01 05:07:35 +1d00h·87.7 天前
Stryker二季度业绩小幅超预期但全年指引基本贴近预期且股价已完成一日重定价
二季度收入约65.9亿美元、调整后EPS 3.69美元，分别略高于市场预期，说明网络事件后的经营恢复好于一季度。
📄 原文Wall St Engine@wallstengine↗ 原文
STRYKER $SYK Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $6.6B (Est. $6.58B) 🟢; +9.4% YoY 🔹 Adj. EPS: $3.69 (Est. $3.49) 🟢; +1…
不做 Stryker（SYK.US）
财报为预定披露且已过一个完整美股交易日；二季度beat被接近预期的全年指引和财报后大跌抵消，LONG/SHORT方向都不够干净，且行情工具超时无法生成可回测ENTER价位。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Stryker此前预告二季度财报新闻稿将在美东7月30日约16:05发布，说明该财报是预定披露事件而非突发低扩散催化。
- 社交账号在财报发布后约2分钟转述收入、EPS、利润率和全年指引摘要。
- WSJ报道确认二季度利润和收入增长、调整后EPS超预期、收入略超预期以及全年指引区间。市场反应:报道称Stryker股价财报后下跌约9.5%至315美元。
关键理由
- 二季度收入约65.9亿美元、调整后EPS 3.69美元，分别略高于市场预期，说明网络事件后的经营恢复好于一季度。
- 全年调整后EPS指引14.95-15.10美元相对14.97美元一致预期只是贴近/小幅覆盖，缺少新的全年上修 surprise。
- 当前研判时点已在2026-07-31美股收盘后，WSJ报道显示财报后Stryker股价已大幅下跌至约315美元，首个可交易窗口已过去。
主要风险
- 财报数字正负混合，市场已用完整交易日重定价，隔夜再追多或追空都缺少清晰剩余edge。
- stock_quote连续超时，无法取得可回测ENTER所需的真实最新价，因此不应输出可执行入场单。
反向证据
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- price_snapshot · 结果未知
原文全文
展开原文 · 921 字
STRYKER $SYK Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $6.6B (Est. $6.58B) 🟢; +9.4% YoY
🔹 Adj. EPS: $3.69 (Est. $3.49) 🟢; +17.9% YoY
🔹 Organic Net Sales Growth: +9.0%
🔹 Adjusted Operating Margin: 27.4%; +170 bps YoY
FY26 Guide:
🔹 Organic Growth: 8.3% to 9.3%; narrowed
🔹 Adj. EPS: $14.95-$15.10 (Est. $14.97) 🟡; narrowed
Other Q2 Metrics:
🔹 Reported Operating Margin: 25.2%
🔹 Reported Net Earnings: $1.3B; +44.3% YoY
Comments:
🔸 “We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter.”
🔸 “As we have seen in the past, the resilience of our teams when faced with challenges was once again on display. With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech.”
🔹 Revenue: $6.6B (Est. $6.58B) 🟢; +9.4% YoY
🔹 Adj. EPS: $3.69 (Est. $3.49) 🟢; +17.9% YoY
🔹 Organic Net Sales Growth: +9.0%
🔹 Adjusted Operating Margin: 27.4%; +170 bps YoY
FY26 Guide:
🔹 Organic Growth: 8.3% to 9.3%; narrowed
🔹 Adj. EPS: $14.95-$15.10 (Est. $14.97) 🟡; narrowed
Other Q2 Metrics:
🔹 Reported Operating Margin: 25.2%
🔹 Reported Net Earnings: $1.3B; +44.3% YoY
Comments:
🔸 “We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter.”
🔸 “As we have seen in the past, the resilience of our teams when faced with challenges was once again on display. With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。